N. Bayman

1.5k total citations · 1 hit paper
48 papers, 950 citations indexed

About

N. Bayman is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Oncology. According to data from OpenAlex, N. Bayman has authored 48 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 13 papers in Radiation and 12 papers in Oncology. Recurrent topics in N. Bayman's work include Lung Cancer Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Advanced Radiotherapy Techniques (13 papers). N. Bayman is often cited by papers focused on Lung Cancer Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (17 papers) and Advanced Radiotherapy Techniques (13 papers). N. Bayman collaborates with scholars based in United Kingdom, Australia and United States. N. Bayman's co-authors include Corinne Faivre‐Finn, Caroline Lee, David Ardron, Tanya Holt, Kathryn Waite, Rachael Barton, Ruth E. Langley, Matthew Nankivell, Elaine McColl and Cheryl Pugh and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

N. Bayman

42 papers receiving 932 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

2016 453 citations P. Mulvenna, Matthew Nankivell et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Bayman United Kingdom	15	753	456	187	147	131	48	950
P.A. Burt United Kingdom	17	1.0k 1.4×	810 1.8×	110 0.6×	117 0.8×	242 1.8×	48	1.4k
Cheryl Pugh United Kingdom	10	970 1.3×	619 1.4×	222 1.2×	102 0.7×	124 0.9×	17	1.1k
L. Trodella Italy	14	469 0.6×	353 0.8×	122 0.7×	140 1.0×	192 1.5×	58	826
Dirk K.M. De Ruysscher Netherlands	15	385 0.5×	330 0.7×	58 0.3×	150 1.0×	52 0.4×	46	701
Lucio Trodella Italy	22	878 1.2×	721 1.6×	150 0.8×	353 2.4×	535 4.1×	68	1.5k
Rie Nakahara Japan	19	752 1.0×	251 0.6×	34 0.2×	269 1.8×	307 2.3×	58	1.2k
Lukas Käsmann Germany	17	510 0.7×	483 1.1×	32 0.2×	221 1.5×	151 1.2×	99	977
Hilke Vorwerk Germany	17	422 0.6×	136 0.3×	73 0.4×	322 2.2×	186 1.4×	49	882
Harvey Quon Canada	17	629 0.8×	97 0.2×	78 0.4×	181 1.2×	93 0.7×	67	884
Irena Oblak Slovenia	17	227 0.3×	416 0.9×	55 0.3×	56 0.4×	344 2.6×	46	681

Countries citing papers authored by N. Bayman

Since Specialization

Citations

This map shows the geographic impact of N. Bayman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Bayman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Bayman more than expected).

Fields of papers citing papers by N. Bayman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Bayman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Bayman. The network helps show where N. Bayman may publish in the future.

Co-authorship network of co-authors of N. Bayman

This figure shows the co-authorship network connecting the top 25 collaborators of N. Bayman. A scholar is included among the top collaborators of N. Bayman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Bayman. N. Bayman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Banfill, Kathryn, N. Bayman, Margaret Harris, et al.. (2025). Integrating Electronic Patient-Reported Outcome Measures (ePROMs) into Personalised Follow-up for Patients after Radiotherapy. A Feasibility Study. Technical Innovations & Patient Support in Radiation Oncology. 35. 100333–100333.

Banfill, Kathryn, Claire Barker, N. Bayman, et al.. (2025). 2469 Reirradiation for Lung Cancer: Investigating Toxicity and Outcomes. Radiotherapy and Oncology. 206. S1355–S1357.

Fornacon-Wood, Isabella, Clara C. Chan, N. Bayman, et al.. (2022). Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer. Frontiers in Oncology. 12. 835844–835844. 7 indexed citations

Mistry, Hitesh, N. Bayman, Clara C. Chan, et al.. (2021). Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Radiotherapy and Oncology. 160. 78–81. 9 indexed citations

Bayman, N., Margaret Harris, L. Pemberton, et al.. (2021). Routine electronic patient reported outcomes measures (ePROMs) for patients with lung cancer. Lung Cancer. 156. S6–S6. 1 indexed citations

Bayman, N., K. Franks, Susan Harden, et al.. (2020). Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. International Journal of Radiation Oncology*Biology*Physics. 109(5). 1341–1348. 15 indexed citations

Kennedy, Jason, Gareth Price, David Woolf, et al.. (2020). Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?. Clinical Oncology. 32(10). 674–684. 9 indexed citations

Gomes, Fábio, Katie Baker, Laura Cove-Smith, et al.. (2019). MA19.09 Assessing Clinical Frailty in Advanced Lung Cancer Patients - An Opportunity to Improve Patient Outcomes?. Journal of Thoracic Oncology. 14(10). S329–S329. 3 indexed citations

Woolf, David, N. Bayman, Margaret Harris, et al.. (2018). The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. Technical Innovations & Patient Support in Radiation Oncology. 7. 11–16. 3 indexed citations

10.

Hudson, Andrew, Clara C. Chan, David Woolf, et al.. (2018). Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. Lung Cancer. 118. 139–147. 7 indexed citations

11.

Bayman, N., David Ardron, Linda Ashcroft, et al.. (2016). Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open. 6(1). e010589–e010589. 16 indexed citations

12.

Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet. 388(10055). 2004–2014. 453 indexed citations breakdown →

13.

Franks, K., Gerard G. Hanna, Susan Harden, et al.. (2016). Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. BMJ Open. 6(4). e010457–e010457. 25 indexed citations

14.

Christodoulou, Maria, N. Bayman, P.A. Burt, et al.. (2014). Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiotherapy and Oncology. 112(2). 244–249. 20 indexed citations

15.

Faivre‐Finn, Corinne, et al.. (2014). PO-0688: Concurrent CTRT (cCTRT) for locally advanced NSCLC followed by consolidation pemetrexed: a phase II study. Radiotherapy and Oncology. 111. S16–S16. 1 indexed citations

16.

Bayman, N., et al.. (2013). How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. Lung Cancer. 83(2). 117–125. 29 indexed citations

17.

Christodoulou, Maria, et al.. (2013). New radiotherapy approaches in locally advanced non-small cell lung cancer. European Journal of Cancer. 50(3). 525–534. 37 indexed citations

18.

Bayman, N., Nooreen Alam, & Corinne Faivre‐Finn. (2010). Radiotherapy for lung cancer in the elderly. Lung Cancer. 68(2). 129–136. 23 indexed citations

19.

Lee, Caroline, N. Bayman, R. Swindell, & Corinne Faivre‐Finn. (2009). Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. Lung Cancer. 66(2). 150–156. 41 indexed citations

20.

Jones, Helen, Andrew Sykes, N. Bayman, et al.. (2008). The impact of lymphovascular invasion on survival in oral carcinoma. Oral Oncology. 45(1). 10–15. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact